The oncology nutrition market size is projected to be valued at US$ 2.07 billion in 2023 and is expected to be valued at US$ 4.87 billion by 2033. The demand for oncology nutrition is likely to record an average CAGR of 8.9% during the forecast period.
Medical nutrition therapy for cancer is crucial for enhancing physical capacity, coping with cancer therapies, and overall quality of life. For businesses functioning in contemporary oncology nutrition products, the fall in tolerance to cancer therapy is anticipated to boost the adoption of oncology nutrition. Furthermore, nutritional screening and evaluation are essential for identifying people who are more likely to be malnourished.
Oncology Nutrition Market Trend Analysis
Creation of elemental formulations and product innovation in terms of non-GMO-based formulas.
Shift in emphasis from parenteral to enteral nutrition.
Rising cancer incidence, particularly the rise of patients receiving treatment for malnutrition.
Rising demand for nutritional feeding in the homecare industry.
Improving the quality of clinical research on nutritional interventions.
Report Attribute
Details
Oncology Nutrition Market Revenue (2023)
US$ 2.07 billion
Market Anticipated Forecast Value (2033)
US$ 4.87 billion
Market Projected Growth Rate (2023 to 2033)
8.9%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Global Oncology Nutrition Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)
Due to technological developments and extensive research, the cancer nutrition supplements market share is anticipated to expand significantly over the next few years. The demand for oncology nutrition is anticipated to pick up steam throughout the evaluation period, even if the nutritional risk is still mostly beneath the radar.
Attributes
Details
Oncology Nutrition Market Size (2018)
US$ 1.33 billion
Market Size (2022)
US$ 1.92 billion
Market (CAGR 2018 to 2022)
7.6%
Due to the worldwide increase in cases of malnutrition brought on by tumors, oncology nutrition is still a crucial topic for healthcare professionals. According to several studies, malnutrition screening in cancer treatment could enhance nutritional evaluation and help patients avoid malnutrition.
Key Oncology Nutrition Market Dynamics
Growth Driving Factors in the Oncology Nutrition Market
A significant driver of the cancer nutrition market's growth is projected to be the huge increase in nutritional waste and nutritional risk among cancer patients. Participants in the market landscape are now investigating the possible advantages of utilizing a multidisciplinary strategy, where focused oncology nutrition guidelines are expected to be crucial to improving the standard of cancer care.
The oncology nutrition companies are anticipated to profit from increased research and development activities as well as the launch of cutting-edge products for cancer patients over the forecasted period. The creation of essential formulas and the advent of new markets are also anticipated to boost the cancer nutrition patent landscape and the pace of future expansion.
Due to these factors, the overall market is anticipated to reach US$ 3.12 billion by the end of 2027. A few key aspects anticipated to drive the expansion of the market for oncology nutrition research in the upcoming years include:
Evolving recommendations
A rise in observational studies
An increase in clinical trials globally
Due to the considerable increase in the use of nutritional evaluation programs, particularly during cancer cachexia and pre-cachexia, the demand for oncology nutrition is predicted to continue to rise. Over the past ten years, data-gathering methods for varied patients' nutritional status have advanced quickly. These developments have led to personalized oncology nutrition therapy and are now recognized as the perfect remedy for cancer patients prone to malnutrition.
Find your sweet spots for generating winning opportunities in this market.
Factors Influencing the Oncology Nutrition Market Challenges
As the number of cancer patients keeps increasing, several nations are dealing with significant healthcare difficulties. About 85% of cancer cases globally, in the opinion of many medical professionals, are related to poor nutrition and a sedentary lifestyle.
The development pace of the oncology nutrition market is likely to be slowed by issues with tube feeling. The poor reimbursement for its usage is likely to hinder the growth of the market for oncology nutrition. Lack of understanding is anticipated to be a new challenge for the oncology nutrition market over the forecast period.
The insufficient and ambiguous recommendations established by authoritative authorities, as a result of which oncology nutrition stayed at the backseat, is one of the most significant issues that market participants in the oncology nutrition industry have had to cope with over several decades.
Key Trends that may govern the Oncology Nutrition Trends from 2023 to 2033
The overall market is growing primarily due to the growth in cancer prevalence. Another significant factor influencing the oncology nutrition market's growth rate is the rising cost of healthcare.
The adoption of oncology nutrition is also anticipated to develop due to improvements in fundamental methods, growing government funding, and rising public and private sector initiatives to increase knowledge of cancer patient nutrition.
Contrarily, obesity and food are to blame for 35% and 30% of all cancer-related mortality, respectively. Eating many nutritious meals might help cancer patients increase their strength and stamina throughout treatment. Nutrient-rich meals are in more demand because they help stop cancer cells from proliferating.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Comparative Analysis of the Adjacent Oncology Nutrition Market
In the broader landscape of oncology, three distinct domains can be identified: oncology nutrition, oncology adjuvants, and generic oncology drugs. As per the data presented in the table, it is noteworthy that from 2023 to 2033, the oncology nutrition market demonstrates a more promising CAGR when compared to the other two markets. This reflects a rising trend in oncology nutrition as healthcare professionals increasingly prioritize personalized nutrition alongside treatment protocols.
Oncology Nutrition Market:
Differentiating Aspects
Oncology Nutrition Market
CAGR (2023 to 2033)
8.9%
Projected Market Value in 2033
US$ 4.87 billion
Growth Factors
Rising awareness about the importance of nutrition in cancer treatment
Opportunities
Development of specialized oncology nutrition products by pharmaceutical companies
Key Trends
Integration of nutritional counseling into comprehensive cancer care programs
Oncology Adjuvants Market:
Differentiating Aspects
Oncology Adjuvants Market
CAGR (2023 to 2033)
4.6%
Projected Market Value in 2033
US$ 868.04 million
Growth Factors
Growing emphasis on combination therapies for enhanced treatment efficacy
Opportunities
Integration of biomarker-driven approaches for better patient stratification
Key Trends
Surge in the development of personalized adjuvant therapies for specific cancer types
Generic Oncology Drugs Market:
Differentiating Aspects
Generic Oncology Drugs Market
CAGR (2023 to 2033)
6%
Projected Market Value in 2033
US$ 46.51 billion
Growth Factors
Increasing acceptance of generic oncology drugs by healthcare professionals
Opportunities
Expansion of the market with the availability of generic versions of complex targeted therapies
Key Trends
Growing adoption of biosimilar oncology drugs, specifically in biologics-based treatments
Segmentation Outlook for the Oncology Nutrition Market
The Gastrointestinal Cancer Segment is Predicted to lead the Market by Cancer Type
The gastrointestinal cancer sector is expected to develop over the research period due to the high incidence of this cancer in the global population.
Attributes
Details
Top Cancer Type
Gastrointestinal Cancer
Market Share in 2023
22.2%
This situation has led to the growth of gastrointestinal cancer nutritional supplements and increased awareness of the importance of nutritional supplement use.
Medical Professionals prefer Enteral Nutrition Parenteral Nutrition Administration
The demand for oncology nutrition is growing because diet provides the ability to fight disease and provides power and endurance against the treatment's side effects.
Attributes
Details
Top Route of Administration Type
Enteral Nutrition
Market Share in 2023
73%
As the number of individuals diagnosed with cancer rises, medical professionals will likely favor the enteral nutrition segment.
Hospitals and Clinics remain the Leading Distribution Channels
The requirement of appropriate medication strategy and prescriptions has resulted in higher sales of all nutrition and supplements market products through hospitals and clinic segments.
Attributes
Details
Top Distribution Channel Type
Hospitals and Clinics
Market Share in 2023
46.8%
So, as per our estimates, this segment is anticipated to remain the leading distribution channel for oncology nutrition products as well through 2033.
Regional Analysis
North America Oncology Nutrition Market Outlook
North America is anticipated to lead the global oncology nutrition market throughout the forecast period. This is due to several important factors, including the increased incidence of cancer and the accessibility of cutting-edge healthcare infrastructure.
The oncology nutrition market in the United States is expected to be worth around US$ 412.6 million. According to a statistic from the American Cancer Society, there will likely be 1.9 million new instances of cancer in the United States this year.
Regional Market Comparison
Global Market Share in Percentage
North America
33.4%
Europe
28.8%
Asia Pacific to Witness High Growth Potential in the Oncology Nutrition Market
FMI projects that the Asia Pacific oncology nutrition market is anticipated to expand faster due to the region's rising prevalence of cancer cases. Additionally, several certification programs and awareness sessions are held locally to inform cancer patients and healthcare professionals about the significance of oncology nutrition.
Regional Market Comparison
Global Market Share in Percentage
United States
29.7%
Germany
7.9%
Japan
3.4%
Europe Oncology Nutrition Market to Expand by Active Awareness Programs
The market in Europe is anticipated to reach a US$ 0.55 billion value by the end of the year 2033. Government programs, new product introductions, and partnerships in cancer nutrition supplements all contribute to market expansion. For instance, the 2022 Oncology Nutrition Symposium was held in June 2022 by the Academy of Nutrition and Dietetics.
The market in the United Kingdom is poised to witness an annual growth rate of 8.3% between 2023 and 2033.
Country wise Insights
The United States oncology nutrition market holds 29.7% of the global market share. Demand for oncology nutrition is predicted to increase in the United States, fueled by rising spending on various cancer medicines. The United States market is witnessing a dynamic shift spurred by the rising percentage of cancer patients and the convergence of technological breakthroughs.
By 2026, the second-leading economy in the world, China, is anticipated to have an oncology nutrition market of US$ 165 million, indicating a CAGR of 11.9% throughout the research. China is projected to keep being one of the countries with the quickest rate of growth in the Asia Pacific oncology nutrition market.
Other significant geographic oncology nutrition markets include Japan and Canada, with growth rates of 7.4% and 7.1%, respectively, predicted for the projected period.
Latin America is anticipated to expand at a 7.6% CAGR throughout the study period, while the Asia Pacific oncology nutrition market is anticipated to reach US$ 19.2 million, driven by countries like Australia, India, and South Korea.
Regional Markets
CAGR (2023 to 2033)
United Kingdom
8.3%
China
11.9%
India
9.4%
Australia
9.6%
Startup Ecosystem
With certain leading pharmaceutical corporations, startups in the oncology nutrition sector are working hard in this area. Clinical studies now include parenteral oncology feeding. Oncology nutrition is projected to become more popular as cancer incidence and the demand for tailored medication and nutrition rise.
In the market for cancer nutrition, collaboration with nutritionists and oncology research institutes is also anticipated to present considerable prospects for companies. For instance, the American biotechnology giant Celgene Corporation teamed up with Savor Health, a provider of specialized nutritional advice to cancer patients.
Competitive Landscape of the Oncology Nutrition Market
New product launches and continuous technological innovations are the key strategies adopted by prominent players in the oncology nutrition market. The healthcare systems organizations are changing due to new research and increased public knowledge of the advantages of oncology nutrition. Clinical nutritionists and oncologists are working more closely to improve oncology nutrition and treatment within the oncology nutrition sector.
The presence of competitors, new product debuts, and partnerships related to the industry under consideration all contribute to the market's growth. According to the report, Esperer launched its nutrition development center in Hyderabad in 2020. The facility in Hyderabad is expected to house a variety of cohesive capabilities, such as investigative workrooms and product development sub-centers, with a dedicated laboratory for analyzing sensory components, packing, and taste.
The leading firms worldwide for oncology nutrition are focused on obtaining regulatory clearances, developing cutting-edge goods, introducing new products, and partnering with and acquiring other businesses. The global market for oncology nutrition is projected to expand due to these leading players' tactics. The following are a few expansion methods used by companies in the oncology nutrition market:
To increase its presence in medical nutrition, Nestle acquired the Allergan business in January 2020.
Smartfish AS and B. Braun worked together to introduce Remune, a medicinal nutrition solution, in September 2019. In 2019 and 2020, B. Braun introduced Remune in over 20 nations. Several other markets in Europe, Asia, and South America followed.
Ina, the intelligent nutrition helper, was introduced by CancerCare in collaboration with Savor Health in 2019. The Ina offers tailored, evidence-based nutrition counseling to help cancer patients eat well and stay fed during treatment.
A three-chamber bag with a unique protein-to-energy ratio called mofKabiven additional Nitrogen was introduced by Fresenius Kabi AG in 2018 in Europe.
The SmartPN tool was introduced in October 2018 by Baxter International Inc. and the American Society for Parenteral and Enteral Nutrition (ASPEN) to reduce clinical malnutrition.
Key Players in the Oncology Nutrition Market
FMC Corporation
Danone India
Abbott
Aceto
B. Braun Melsungen AG
Baxter
Fresenius Kabi AG
Global Health Products, Inc.
Hormel Foods Corporation
Mead Johnson & Company, LLC
Meiji Holdings Co., Ltd
Nestlé S.A.
BioSig Technologies, Inc.
Auris Health, Inc.
Scope of the Report
Attribute
Details
Growth Rate
CAGR of 8.9% from 2023 to 2033
Base Year of Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ million and F-CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis
Key Segments Covered
By Cancer Type
By End Use
By Region
Regions Covered
North America
Latin America
Europe
East Asia
South Asia
The Middle East & Africa
Oceania
Key Countries Profiled
The United States
Canada
Brazil
Mexico
Germany
Italy
France
United Kingdom
Spain
Russia
China
Japan
GCC Countries
Australia
Key Companies Profiled
FMC Corporation
Danone India
Abbott
Aceto
B. Braun Melsungen AG
Baxter
Fresenius Kabi AG
Global Health Products, Inc.
Hormel Foods Corporation
Mead Johnson & Company, LLC
Meiji Holdings Co., Ltd
Nestlé S.A.
BioSig Technologies, Inc.
Auris Health, Inc.
Key Segments
By Cancer Type:
Head & Neck Cancer
Stomach & Gastrointestinal Cancers
Blood Cancer
Breast Cancer
Lung Cancer
Other cancers
By End Use:
Hospitals & Clinics
Home Care
Others
By Region:
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe (RoE)
Asia Pacific
Latin America
The Middle East and Africa
Frequently Asked Questions
What is the Oncology Nutrition Market Size in 2023?
The overall market is estimated to be around US$ 2.07 billion in 2023.
Who are the Market Leaders in Oncology Nutrition?
FMC, Danone, and Abbott are some of the leading market players.
What is Oncology Nutrition?
Proper management of diet intake of patients undergoing cancer treatment.
How Big is the Clinical Nutrition Market?
The hospitals and clinical market segment contributed 46.8% of revenue in 2022.
What are the Trends in the Oncology Nutrition Industry?
Collaborations with nutritionists and oncology research institutes are driving the market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Cancer Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cancer Type, 2023 to 2033
5.3.1. Head & Neck Cancer
5.3.2. Stomach & Gastrointestinal Cancers
5.3.3. Blood Cancer
5.3.4. Breast Cancer
5.3.5. Lung Cancer
5.3.6. Other cancers
5.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Cancer Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033
6.3.1. Hospitals
6.3.2. Home Care
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Cancer Type
8.2.3. By End Use
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Cancer Type
8.3.3. By End Use
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Cancer Type
9.2.3. By End Use
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Cancer Type
9.3.3. By End Use
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Cancer Type
10.2.3. By End Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Cancer Type
10.3.3. By End Use
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Cancer Type
11.2.3. By End Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Cancer Type
11.3.3. By End Use
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Cancer Type
12.2.3. By End Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Cancer Type
12.3.3. By End Use
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Cancer Type
13.2.3. By End Use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Cancer Type
13.3.3. By End Use
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Cancer Type
14.2.3. By End Use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Cancer Type
14.3.3. By End Use
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Cancer Type
15.1.2.2. By End Use
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Cancer Type
15.2.2.2. By End Use
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Cancer Type
15.3.2.2. By End Use
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Cancer Type
15.4.2.2. By End Use
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Cancer Type
15.5.2.2. By End Use
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Cancer Type
15.6.2.2. By End Use
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Cancer Type
15.7.2.2. By End Use
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Cancer Type
15.8.2.2. By End Use
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Cancer Type
15.9.2.2. By End Use
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Cancer Type
15.10.2.2. By End Use
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Cancer Type
15.11.2.2. By End Use
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Cancer Type
15.12.2.2. By End Use
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Cancer Type
15.13.2.2. By End Use
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Cancer Type
15.14.2.2. By End Use
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Cancer Type
15.15.2.2. By End Use
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Cancer Type
15.16.2.2. By End Use
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Cancer Type
15.17.2.2. By End Use
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Cancer Type
15.18.2.2. By End Use
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Cancer Type
15.19.2.2. By End Use
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Cancer Type
15.20.2.2. By End Use
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Cancer Type
15.21.2.2. By End Use
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Cancer Type
15.22.2.2. By End Use
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Cancer Type
15.23.2.2. By End Use
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Cancer Type
16.3.3. By End Use
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. FMC Corporation
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Danone India
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Abbott
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Aceto
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. B. Braun Melsungen AG
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Baxter
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Fresenius Kabi AG
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Global Health Products, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Hormel Foods Corporation
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Mead Johnson & Company, LLC
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Meiji Holdings Co., Ltd
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Nestlé S.A.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. BioSig Technologies, Inc.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Auris Health, Inc.
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Western Europe Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 12: Western Europe Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 15: Eastern Europe Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: East Asia Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Cancer Type, 2018 to 2033
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by End Use, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End Use, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 13: Global Market Attractiveness by Cancer Type, 2023 to 2033
Figure 14: Global Market Attractiveness by End Use, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End Use, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 28: North America Market Attractiveness by Cancer Type, 2023 to 2033
Figure 29: North America Market Attractiveness by End Use, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End Use, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Cancer Type, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End Use, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Western Europe Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 47: Western Europe Market Value (US$ Million) by End Use, 2023 to 2033
Figure 48: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Western Europe Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 55: Western Europe Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 58: Western Europe Market Attractiveness by Cancer Type, 2023 to 2033
Figure 59: Western Europe Market Attractiveness by End Use, 2023 to 2033
Figure 60: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Eastern Europe Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 62: Eastern Europe Market Value (US$ Million) by End Use, 2023 to 2033
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 73: Eastern Europe Market Attractiveness by Cancer Type, 2023 to 2033
Figure 74: Eastern Europe Market Attractiveness by End Use, 2023 to 2033
Figure 75: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 76: South Asia and Pacific Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 77: South Asia and Pacific Market Value (US$ Million) by End Use, 2023 to 2033
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 88: South Asia and Pacific Market Attractiveness by Cancer Type, 2023 to 2033
Figure 89: South Asia and Pacific Market Attractiveness by End Use, 2023 to 2033
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 91: East Asia Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 92: East Asia Market Value (US$ Million) by End Use, 2023 to 2033
Figure 93: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: East Asia Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 100: East Asia Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 101: East Asia Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 103: East Asia Market Attractiveness by Cancer Type, 2023 to 2033
Figure 104: East Asia Market Attractiveness by End Use, 2023 to 2033
Figure 105: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 106: Middle East and Africa Market Value (US$ Million) by Cancer Type, 2023 to 2033
Figure 107: Middle East and Africa Market Value (US$ Million) by End Use, 2023 to 2033
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Cancer Type, 2018 to 2033
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by End Use, 2018 to 2033
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by End Use, 2023 to 2033
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by End Use, 2023 to 2033
Figure 118: Middle East and Africa Market Attractiveness by Cancer Type, 2023 to 2033
Figure 119: Middle East and Africa Market Attractiveness by End Use, 2023 to 2033
Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
